GlassScriptPhysician profile
Blake S Chapman
NPI 1205324209
$447.20
in general payments reported to CMS, 2019-2025
16 companies · $30.25 in 2025
The $30.25 reported for 2025 was less than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $67.86 · 2022: $156 · 2023: $141 · 2024: $51.50 · 2025: $30.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $223.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $84.58 | 2021-2024 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $70.24 | 2022-2023 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.43 | 2021-2023 | Spiriva Respimat |
| Abbvie INC. | $45.52 | 2023 | Vraylar |
| Astellas Pharma US INC | $35.96 | 2022-2023 | Veozah |
| Pulmonx Corporation | $27.03 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Eisai INC. | $21.15 | 2022 | |
| Aimmune Therapeutics, INC. | $16.74 | 2025 | Zenpep |
| Sanofi Pasteur INC. | $16.64 | 2023 | |
| Novo Nordisk INC | $13.51 | 2025 | Wegovy |
| Pfizer INC. | $13.41 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.37 | 2023 | Eliquis |
| Baxter Healthcare | $13.35 | 2023 | Hillrom - Life 2000 Ventilation System |
| Morphosys, US INC. | $13.30 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.97 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.